vs
Side-by-side financial comparison of ARS Pharmaceuticals, Inc. (SPRY) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $28.1M, roughly 1.1× ARS Pharmaceuticals, Inc.). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -147.1%, a 134.2% gap on every dollar of revenue. On growth, SYPRIS SOLUTIONS INC posted the faster year-over-year revenue change (-9.5% vs -67.6%).
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
SPRY vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.1M | $30.3M |
| Net Profit | $-41.3M | $-3.9M |
| Gross Margin | — | 4.6% |
| Operating Margin | -147.6% | -10.9% |
| Net Margin | -147.1% | -12.9% |
| Revenue YoY | -67.6% | -9.5% |
| Net Profit YoY | -182.8% | -2992.6% |
| EPS (diluted) | $-0.41 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.1M | $30.3M | ||
| Q3 25 | $32.5M | $28.7M | ||
| Q2 25 | $15.7M | $31.4M | ||
| Q1 25 | $8.0M | $29.5M | ||
| Q4 24 | $86.6M | $33.4M | ||
| Q3 24 | $2.1M | $35.7M | ||
| Q2 24 | $500.0K | $35.5M | ||
| Q1 24 | $0 | $35.6M |
| Q4 25 | $-41.3M | $-3.9M | ||
| Q3 25 | $-51.2M | $517.0K | ||
| Q2 25 | $-44.9M | $-2.1M | ||
| Q1 25 | $-33.9M | $-899.0K | ||
| Q4 24 | $49.9M | $135.0K | ||
| Q3 24 | $-19.1M | $390.0K | ||
| Q2 24 | $-12.5M | $16.0K | ||
| Q1 24 | $-10.3M | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | -147.6% | -10.9% | ||
| Q3 25 | -163.7% | -6.1% | ||
| Q2 25 | -302.9% | -4.6% | ||
| Q1 25 | -466.3% | -0.4% | ||
| Q4 24 | 54.5% | 3.9% | ||
| Q3 24 | -1051.6% | 4.8% | ||
| Q2 24 | -3068.0% | 3.6% | ||
| Q1 24 | — | -3.9% |
| Q4 25 | -147.1% | -12.9% | ||
| Q3 25 | -157.4% | 1.8% | ||
| Q2 25 | -285.6% | -6.5% | ||
| Q1 25 | -425.7% | -3.0% | ||
| Q4 24 | 57.7% | 0.4% | ||
| Q3 24 | -925.0% | 1.1% | ||
| Q2 24 | -2503.2% | 0.0% | ||
| Q1 24 | — | -6.2% |
| Q4 25 | $-0.41 | $-0.17 | ||
| Q3 25 | $-0.52 | $0.02 | ||
| Q2 25 | $-0.46 | $-0.09 | ||
| Q1 25 | $-0.35 | $-0.04 | ||
| Q4 24 | $0.52 | $0.00 | ||
| Q3 24 | $-0.20 | $0.02 | ||
| Q2 24 | $-0.13 | $0.00 | ||
| Q1 24 | $-0.11 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.0M | — |
| Total DebtLower is stronger | $96.4M | — |
| Stockholders' EquityBook value | $114.3M | $17.8M |
| Total Assets | $327.7M | $107.8M |
| Debt / EquityLower = less leverage | 0.84× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $245.0M | — | ||
| Q3 25 | $288.2M | — | ||
| Q2 25 | $240.1M | — | ||
| Q1 25 | $275.7M | — | ||
| Q4 24 | $314.0M | — | ||
| Q3 24 | $204.6M | — | ||
| Q2 24 | $218.7M | — | ||
| Q1 24 | $223.6M | — |
| Q4 25 | $96.4M | — | ||
| Q3 25 | $96.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $114.3M | $17.8M | ||
| Q3 25 | $147.7M | $20.0M | ||
| Q2 25 | $192.3M | $18.7M | ||
| Q1 25 | $229.0M | $19.0M | ||
| Q4 24 | $256.8M | $19.6M | ||
| Q3 24 | $201.0M | $18.2M | ||
| Q2 24 | $215.2M | $19.0M | ||
| Q1 24 | $223.9M | $20.8M |
| Q4 25 | $327.7M | $107.8M | ||
| Q3 25 | $372.8M | $112.5M | ||
| Q2 25 | $313.5M | $105.8M | ||
| Q1 25 | $327.3M | $110.2M | ||
| Q4 24 | $351.2M | $119.4M | ||
| Q3 24 | $217.6M | $121.6M | ||
| Q2 24 | $222.0M | $124.2M | ||
| Q1 24 | $227.6M | $129.0M |
| Q4 25 | 0.84× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-43.5M | $-1.1M |
| Free Cash FlowOCF − Capex | — | $-1.5M |
| FCF MarginFCF / Revenue | — | -5.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-43.5M | $-1.1M | ||
| Q3 25 | $-47.0M | $-178.0K | ||
| Q2 25 | $-39.6M | $1.1M | ||
| Q1 25 | $-40.7M | $-5.5M | ||
| Q4 24 | $42.0M | $2.3M | ||
| Q3 24 | $-14.5M | $-4.8M | ||
| Q2 24 | $-7.3M | $6.2M | ||
| Q1 24 | $-6.7M | $-1.7M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | $-47.2M | $-390.0K | ||
| Q2 25 | $-39.6M | $941.0K | ||
| Q1 25 | $-40.8M | $-5.5M | ||
| Q4 24 | $41.7M | $1.9M | ||
| Q3 24 | $-14.6M | $-4.9M | ||
| Q2 24 | $-7.3M | $6.0M | ||
| Q1 24 | $-6.8M | $-2.0M |
| Q4 25 | — | -5.0% | ||
| Q3 25 | -145.4% | -1.4% | ||
| Q2 25 | -252.2% | 3.0% | ||
| Q1 25 | -512.1% | -18.8% | ||
| Q4 24 | 48.2% | 5.7% | ||
| Q3 24 | -706.3% | -13.8% | ||
| Q2 24 | -1463.4% | 16.8% | ||
| Q1 24 | — | -5.7% |
| Q4 25 | 0.0% | 1.3% | ||
| Q3 25 | 0.6% | 0.7% | ||
| Q2 25 | 0.3% | 0.5% | ||
| Q1 25 | 1.1% | 0.0% | ||
| Q4 24 | 0.3% | 1.2% | ||
| Q3 24 | 6.8% | 0.4% | ||
| Q2 24 | 7.6% | 0.5% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.84× | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
